Teneligliptin, a DPP-4 Inhibitor, Improves Vascular Endothelial Function via Divergent Actions Including Changes in Circulating Endothelial Progenitor Cells.
Naoyuki AkashiTomio UmemotoHodaka YamadaTakayuki FujiwaraKei YamamotoYousuke TaniguchiKenichi SakakuraHiroshi WadaShin-Ichi MomomuraHideo FujitaPublished in: Diabetes, metabolic syndrome and obesity : targets and therapy (2023)
Teneligliptin improved FMD through a mechanism other than increasing the number of circulating EPCs.
Keyphrases